Autolus Therapeutics' obe-cel, branded Aucatzyl, is the first CAR-T therapy approved without a REMS, highlighting its safety and unique mechanism.

In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Autolus Therapeutics (AUTL – Research ...

Arkadios Wealth Advisors acquired a new position in shares of Autolus Therapeutics plc (NASDAQ:AUTL – Free Report) during the ...

Autolus Therapeutics received acceptance for an oral presentation and three poster presentations at the prestigious 2025 Tandem Meetings, highlighting their commitment to disseminating research ...

In a report released today, Gil Blum from Needham maintained a Buy rating on Autolus Therapeutics (AUTL – Research Report), with a price target of $10.00. Discover outperforming stocks and ...

Shares of NASDAQ AUTL opened at $2.30 on Monday. Autolus Therapeutics has a 12 month low of $2.07 and a 12 month high of $7.37. The stock has a 50 day moving average of $2.83 and a 200-day moving ...

Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies to patients, today announces ...

LONDON, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing next-generation programmed T cell therapies ...

LONDON, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed ...

In this article, we are going to take a look at where Autolus Therapeutics plc (NASDAQ:AUTL) stands against the other best biotech penny stocks to invest in now. Goldman Sachs has spotlighted an ...

LONDON, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces ...